Flu season is here, and everyone should be thinking about how to stay healthy as the risk of getting the flu gets higher. Last flu season, our region experienced two waves of flu causing hospitalizations and severe illness for thousands of local residents. This year, the Seattle Flu Study is inviting the Seattle community to join them in finding new…
For years, leukemia doctors have been plagued by a toxic trade-off: A bull’s-eye for certain cancer-killing drugs also appears on some normal blood stem cells. Hitting the mark means harming healthy and diseased cells alike. Scientists at Fred Hutchinson Cancer Research Center want to get rid of that trade-off altogether. Their strategy: remove the bull’s-eye from normal cells while leaving…
Researchers at Seattle’s Fred Hutchinson Cancer Research Center have demonstrated the effectiveness of a new method for getting immune cells to fight solid tumors — by spreading them like jam onto ultra-thin sheets of metal mesh, and then laying the mesh onto the tumors. So far, the technique for delivering genetically engineered T cells has been used only on mice — but…
As I prepare to leave my post as leader of Fred Hutchinson Cancer Research Center, my thoughts are turning more than ever toward the next generation of scientists. They will shape our future in a field that is being transformed daily by new discoveries and new technologies. They will work the laboratory benches, crunch the data and envision bold new ways to…
A common virus that is harmless to most individuals may produce an important biomarker in determining the prognosis of brain cancer patients, according to a recent study published by a student researcher at the University of Cincinnati. Patients with glioblastomas or malignant brain tumors, face a difficult future. The disease is fatal, and only about 5 percent of patients are…
Stephen Smith, Ph.D., had been waiting for a certain kind of dataset for a long time. The Allen Institute neuroscientist has a driving interest in brain diversity — not in the sense of how one person’s brain is different from another’s, but in the rich and incredible variation within a single brain. There are a lot of different ways to explore this…
A foundation of the drug discovery process—high throughput screening—is fraught with limitations. A new technique, sci-Plex, uses nuclear hashing to profile and quantify gene expression in single cells in response to thousands of independent perturbations at single-cell resolution. The technology holds promise for drug discovery of drugs for cancer, infection, prenatal medicine, and other research. “Earlier this year, we reached…
A new global study shows that an immunotherapy drug can delay the onset of Type 1 Diabetes for two years in high risk kids and adults. A set of twins is living proof. Twins Megan and Madeline Coder were different in one way: Megan was diagnosed with diabetes at age nine. As her twin and having four of five proteins that target insulin-making cells,…
Omeros Corporation (Nasdaq: OMER) today announced positive data from its pivotal clinical trial of the company’s novel investigational complement inhibitor narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a frequently lethal complication of HSCT. These preliminary data were recently provided to FDA as part of the company’s ongoing interactions with the Agency on the narsoplimab Biologics License Application (BLA).…
Today, PATH announced that its Board of Directors has unanimously chosen global development leader Nikolaj Gilbert as the organization’s next President and Chief Executive Officer to lead PATH’s global efforts to accelerate health equity through innovation and partnerships. Mr. Gilbert will join PATH on January 6, 2020, and will also serve as the Managing Director of Foundation for Appropriate Technology…